Progestagen contraceptives;La contraception progestative

Medecine Therapeutique

Volumn 6, Issue 5, 2000, Pages 399-404

  Couzinet, Béatrice ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; GESTAGEN; HYDROXYPROGESTERONE; NANDROLONE; PROGESTERONE DERIVATIVE;

CONTRACEPTION; HORMONAL THERAPY; PREGNANCY; SHORT SURVEY;

EID: 0033911299     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. McCann M.F., Potter L.S. 1994. Progestin only oral contraception : a comprehensive review. Contraception 50 : S1-S198.
2. Bardin C.W. 1983. The androgenic, anti-androgenic and synandrogenic actions of progestins. In : Bardin C.W., Milgrom E., Mauvais Jarvis P. Progesterone and progestins. New York, Raven Press, 135-147.
3. Paris J., Fournau P., Granero M., Lanquetin A., Thévenot R. 1986. Pharmacological profile of the new pituitary-gonadic suppressant 17β-Acetoxy-5α, 17α-pregn-2-ene-20-yne. Arzneim-Forsch. Drug Res 36 : 1069-1074.
4. Couzinet B., Young J., Brailly S., Chanson P., Thomas J.L., Schaison G. 1996. The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor. J Clin Endocrinol Metab 81 : 4218-4223.
5. Conard J., et al. 1980. Antithromobin III content and antithrombin activity in estrogen progestogen and progestogen only treated women. Thromb Res 18 : 675-681.
6. Hirvonen G., Malkönen M., Manninen V. 1981. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 304 : 560-565.
7. Bardin C.W., Sivin I. 1992. Norplant : the first implantable contraception. In : Sitruk Ware R., Bardin C.W. Contraception. New York, Marcel Dekker, pp 23-39.
8. Mishell D.R. 1983. Progestins in contraception-Present and future. In : Bardin C.W., Milgrom E., Mauvais Jarvis P. Progesterone and progestins. New York, Raven Press, 383-394.
9. Pelissier C., et al. 1994. Action antiovulatoire de l'acétate de chlormadinone. Contracept Fertl Sex 22 : 37-40.
10. Couzinet B., et al. 1999. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab 84 : 4191-4196.
11. Ojasoo T., Raynaud J.P. 1983. Receptor binding profiles of progestins. In : Jasonni V.M., Nenci I., Flamigni C., eds. Steroids and endometrial cancer. New York, RavenPress, 11-28.
12. Basdevant A., Pelissier C., Conard J., Degrelle, Guyene T.T., Thomas J.L. 1991. Effects of Nomegestrol acetate (5 mg/day) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 44 : 599-605.
13. Tikkanen M.J., Nikkilä E.A., Kuusi T., Sipinen S. 1982. High density lipoprotein-2 and hepatic lipase : reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 54 : 1113-1117.
14. Dorangeon P., Thomas J.L., Gillery P., Lumbroso M., Hazard M.C. 1992. Short term effects on lipids and lipoproteins of two progestogens used in postmenomausal replacement therapy. European J Clin Res 3 : 187-193.
15. Conard J., et al. 1995. Cardiovascular risk factors and combined estrogen-progestin replacement therapy : a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 64 : 957-962.
16. Dorangeon P., Thomas J.L., Choisy H., Lumbroso M., Hazard M.C. 1993. Effects of nomegestrol acetate on carbohydrate metabolism. Diabete & Metabolisme 19 : 441-445.